Salzmann Peter's most recent trade in Immunovant Inc was a trade of 8,321 Common Stock done at an average price of $14.9 . Disclosure was reported to the exchange on April 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 14.89 per share. | 16 Apr 2025 | 8,321 | 1,178,191 (2%) | 0% | 14.9 | 123,900 | Common Stock |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 09 Apr 2025 | 28,094 | 1,186,512 (2%) | 0% | 13.0 | 364,941 | Common Stock |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 374,395 | 374,395 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 265,820 | 1,214,606 (2%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.86 per share. | 19 Feb 2025 | 15,439 | 948,786 (1%) | 0% | 20.9 | 322,058 | Common Stock |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 23.81 per share. | 15 Jan 2025 | 8,352 | 964,640 (1%) | 0% | 23.8 | 198,861 | Common Stock |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.19 per share. | 15 Jan 2025 | 415 | 964,225 (1%) | 0% | 24.2 | 10,039 | Common Stock |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 20 Nov 2024 | 16,692 | 978,097 (1%) | 0% | 25.4 | 424,811 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 16 Oct 2024 | 9,095 | 994,789 (1%) | 0% | 28.8 | 261,845 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 09 Oct 2024 | 4,460 | 1,003,884 (1%) | 0% | 29.6 | 131,838 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 21 Aug 2024 | 14,470 | 1,008,942 (1%) | 0% | 31.8 | 460,725 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 21 Aug 2024 | 598 | 1,008,344 (1%) | 0% | 32.3 | 19,327 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 17 Jul 2024 | 8,175 | 1,023,922 (1%) | 0% | 29.6 | 242,307 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 17 Jul 2024 | 510 | 1,023,412 (1%) | 0% | 30.6 | 15,581 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 09 Jul 2024 | 4,619 | 1,032,097 (1%) | 0% | 28.1 | 129,609 | Common Stock | |
| Corbus Pharmaceuticals Hol... | Peter Salzmann | Director | 30 May 2024 | 2,783 | 2,783 (0%) | 0% | 0 | Common Stock, par value $0.0001 per share | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 22 May 2024 | 16,163 | 1,036,716 (1%) | 0% | 29.7 | 479,233 | Common Stock | |
| Corbus Pharmaceuticals Hol... | Peter Salzmann | Director | 16 May 2024 | 2,783 | 2,783 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 17 Apr 2024 | 26,365 | 1,060,593 (1%) | 0% | 28.8 | 759,312 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 17 Apr 2024 | 7,714 | 1,052,879 (1%) | 0% | 29.9 | 230,957 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 09 Apr 2024 | 4,807 | 1,086,958 (1%) | 0% | 31.2 | 149,882 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 02 Apr 2024 | 200,667 | 200,667 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 02 Apr 2024 | 160,534 | 1,091,765 (1%) | 0% | 0 | Common Stock | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 22 Feb 2024 | 13,454 | 931,231 (1%) | 0% | 36.1 | 486,362 | Common Stock | |
| Immunovant Inc | Salzmann Peter | Director, Chief Executive Officer | 05 Jan 2024 | 3,824 | 944,685 (1%) | 0% | 38.6 | 147,568 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 30 Aug 2023 | 50,866 | 975,873 (1%) | 0% | 22.0 | 1,117,526 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 30 Aug 2023 | 5,908 | 969,965 (1%) | 0% | 22.5 | 132,812 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 14 Aug 2023 | 91,744 | 1,038,053 (1%) | 0% | 21.3 | 1,957,817 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 14 Aug 2023 | 11,314 | 1,026,739 (1%) | 0% | 22.0 | 249,361 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 07 Aug 2023 | 101,339 | 1,129,797 (2%) | 0% | 21.7 | 2,202,096 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 12 Jul 2023 | 3,233 | 1,231,136 (2%) | 0% | 19.7 | 63,787 | Common Stock | |
| Corbus Pharmaceuticals Hol... | Peter Salzmann | Director | 18 May 2023 | 5,300 | 5,300 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 18 Apr 2023 | 3,395 | 1,234,369 (2%) | 0% | 15.3 | 51,842 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 12 Apr 2023 | 316,585 | 316,585 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 12 Apr 2023 | 243,832 | 1,237,764 (2%) | 0% | 0 | Common Stock | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 11 Jan 2023 | 4,021 | 993,932 (1%) | 0% | 16.8 | 67,553 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 13 Oct 2022 | 2,793 | 997,953 (1%) | 0% | 9.2 | 25,640 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 28 Sep 2022 | 1,605 | 1,000,746 (1%) | 0% | 4.7 | 7,495 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 30 Aug 2022 | 1,644 | 1,002,351 (1%) | 0% | 5.8 | 9,585 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 17 Aug 2022 | 678,592 | 678,592 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 17 Aug 2022 | 451,264 | 1,003,995 (1%) | 0% | 0 | Common Stock | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 27 Jul 2022 | 1,528 | 552,731 (0%) | 0% | 4.3 | 6,525 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 29 Jun 2022 | 1,376 | 554,259 (0%) | 0% | 4.0 | 5,532 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 24 May 2022 | 1,471 | 555,635 (0%) | 0% | 3.8 | 5,575 | Common Stock | |
| Corbus Pharmaceuticals Hol... | Peter Salzmann | Director | 18 May 2022 | 79,600 | 79,600 | - | - | Stock Option(right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 27 Apr 2022 | 1,622 | 557,106 (0%) | 0% | 4.7 | 7,656 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 24 Mar 2022 | 19,227 | 558,728 (0%) | 0% | 5.9 | 113,439 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 07 Jan 2022 | 125,158 | 577,955 (1%) | 0% | 7.3 | 907,396 | Common Stock | |
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 11 Sep 2021 | 464,700 | 464,700 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 11 Sep 2021 | 464,700 | 0 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 11 Sep 2021 | 430,700 | 430,700 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 11 Sep 2021 | 430,700 | 0 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 03 Aug 2021 | 570,613 | 703,113 (1%) | 1% | 0 | Common Stock | ||
| Corbus Pharmaceuticals Hol... | Peter Salzmann | Director | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | ||
| Corbus Pharmaceuticals Hol... | Peter Salzmann | Director | 17 Jun 2021 | 58,200 | 58,200 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 19 Mar 2021 | 464,700 | 464,700 | - | - | Stock Option (right to buy) | ||
| Immunovant Inc | Peter Salzmann | Director, Chief Executive Officer | 19 Mar 2021 | 132,500 | 132,500 (0%) | 0% | 0 | Common Stock |